Pacific Biosciences of California Inc. Stock
Heavy losses for Pacific Biosciences of California Inc. today as the stock fell by -€0.103 (-5.740%).
Currently there is a rather positive sentiment for Pacific Biosciences of California Inc. with 10 Buy predictions and 5 Sell predictions.
With a target price of 10 € there is potential for a 504.38% increase which would mean more than doubling the current price of 1.65 € for Pacific Biosciences of California Inc..
Our community identified positive and negative aspects for Pacific Biosciences of California Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pacific Biosciences of California Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Pacific Biosciences of California Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacific Biosciences of California Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pacific Biosciences of California Inc. | -5.740% | -4.270% | 6.721% | -85.712% | -82.332% | -92.537% | -72.946% |
MicroVision Inc | 1.540% | 1.061% | -22.305% | -75.568% | -57.767% | -91.814% | 37.272% |
Fonar Corp. New | -1.420% | -0.714% | -6.711% | -13.125% | -21.469% | -6.081% | -19.186% |
Allscripts Healthcare | -2.780% | -2.778% | -4.110% | -35.185% | -24.324% | -49.275% | -19.159% |
Comments
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $7.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat